Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-Myositis
ISRCTN75158615Phase 2Recruiting
- Sponsor
- Advanced Clinical
- Start
- Dec 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 2, open-label trial of resecabtagene autoleucel in Autoimmune Myopathies, dermatomyositis (DM), antisynthetase syndrome (ASSD) and 4 more (2 cohorts), sponsored by Advanced Clinical. Primary endpoint: Adverse events within 28 days. Started Dec 2023; status: recruiting.
02
Drugs
resecabtagene autoleucel
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)antisynthetase syndrome (ASSD)immune-mediated necrotizing myopathy (IMNM)juvenile myositis (JM)
Beyond the preview
Go deeper on ISRCTN75158615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN75158615.